结核病免疫辅助治疗现状与挑战

doi:10.19982/j.issn.1000-6621.20220346

摘要/Abstract

摘要：

关键词: 结核, 免疫, 治疗应用, 评论

中图分类号:

安慧茹, 吴雪琼. 结核病免疫辅助治疗现状与挑战[J]. 中国防痨杂志, 2022, 44(10): 983-986. doi: 10.19982/j.issn.1000-6621.20220346

参考文献 30

[1]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[2]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[3]	Sampath P, Moideen K, Ranganathan UD, et al. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol, 2018, 9:1726. doi: 10.3389/fimmu.2018.01726. doi: 10.3389/fimmu.2018.01726 pmid: 30105020
[4]	Croft M. Co-stimulatory members of the TNFR family:keys to effective T-cell immunity? Nat Rev Immunol, 2003, 3(8):609-620. doi: 10.1038/nri1148. doi: 10.1038/nri1148 URL
[5]	Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol, 2009, 27:393-422. doi: 10.1146/annurev.immunol.021908.132703. doi: 10.1146/annurev.immunol.021908.132703
[6]	Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4(3):288-293. doi: 10.1038/mi.2011.10. doi: 10.1038/mi.2011.10 pmid: 21451503
[7]	Morgan J, Muskat K, Tippalagama R, et al. Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Immunol Rev, 2021, 301(1):10-29. doi: 10.1111/imr.12963. doi: 10.1111/imr.12963 pmid: 33751597
[8]	An HR, Bai XJ, Liang JQ, et al. The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis. Clin Respir J, 2022, 16(5):369-379. doi: 10.1111/crj.13490. doi: 10.1111/crj.13490 URL
[9]	Guglielmetti L, Cazzadori A, Conti M, et al. Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay. Int J Tuberc Lung Dis, 2013, 17(6):825-828. doi: 10.5588/ijtld.12.0361. doi: 10.5588/ijtld.12.0361 pmid: 23676170
[10]	Morais-Papini TF, Coelho-Dos-Reis JGA, Wendling APB, et al. Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection. Immunobiology, 2017, 222(11):1014-1024. doi: 10.1016/j.imbio.2017.05.016. doi: S0171-2985(17)30099-2 pmid: 28619539
[11]	傅小燕, 吴桂辉, 黄涛, 等. 活动性肺结核合并糖尿病患者的T细胞亚群与血糖水平的相关性研究. 中西医结合心血管病电子杂志, 2018, 6(34):71. doi: 10.16282/j.cnki.cn11-9336/r.2018.34.057. doi: 10.16282/j.cnki.cn11-9336/r.2018.34.057
[12]	Schurz H, Daya M, Möller M, et al. TLR1, 2, 4, 6 and 9 Variants Associated with Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(10):e0139711. doi: 10.1371/journal.pone.0139711. doi: 10.1371/journal.pone.0139711
[13]	Sadki K, Lamsyah H, Rueda B, et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J Genet Genomics, 2010, 37(4):257-264. doi: 10.1016/s1673-8527(09)60044-8. doi: 10.1016/S1673-8527(09)60044-8 pmid: 20439102
[14]	Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe, 2008, 3(6):399-407. doi: 10.1016/j.chom.2008.05.006. doi: 10.1016/j.chom.2008.05.006 pmid: 18541216
[15]	Boisson-Dupuis S. The monogenic basis of human tuberculosis. Hum Genet, 2020, 139(6/7):1001-1009. doi: 10.1007/s00439-020-02126-6. doi: 10.1007/s00439-020-02126-6 URL
[16]	Ogishi M, Yang R, Aytekin C, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med, 2021, 27(9):1646-1654. doi: 10.1038/s41591-021-01388-5. doi: 10.1038/s41591-021-01388-5 pmid: 34183838
[17]	Pires D, Marques J, Pombo JP, et al. Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages. Sci Rep, 2016, 6:32247. doi: 10.1038/srep32247. doi: 10.1038/srep32247 URL
[18]	Li F, Feng L, Jin C, et al. LpqT improves mycobacteria survival in macrophages by inhibiting TLR2 mediated inflammatory cytokine expression and cell apoptosis. Tuberculosis (Edinb), 2018, 111:57-66. doi: 10.1016/j.tube.2018.05.007. doi: 10.1016/j.tube.2018.05.007 URL
[19]	Portal-Celhay C, Tufariello JM, Srivastava S, et al. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4⁺ T-cell activation. Nat Microbiol, 2016, 2:16232. doi: 10.1038/nmicrobiol.2016.232. doi: 10.1038/nmicrobiol.2016.232 pmid: 27918526
[20]	Urazova OI, Novitskii VV, Kolobovnikova YV, et al. Factors of Suppression of Immune Response in Patients with Pulmonary Tuberculosis and Eosinophilia. Bull Exp Biol Med, 2015, 159(3):323-326. doi: 10.1007/s10517-015-2952-3. doi: 10.1007/s10517-015-2952-3 URL
[21]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020, 577(7792):682-688. doi: 10.1038/s41586-019-1915-7. doi: 10.1038/s41586-019-1915-7 URL
[22]	中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版).中国防痨杂志, 2022, 44(1): 9-27. doi: 10.19982/j.issn.1000-6621.20210680. doi: 10.19982/j.issn.1000-6621.20210680
[23]	Khan TA, Mazhar H, Saleha S, et al. Interferon-Gamma Improves Macrophages Function against M.tuberculosis in Multidrug-Resistant Tuberculosis Patients. Chemother Res Pract, 2016, 2016:7295390. doi: 10.1155/2016/7295390. doi: 10.1155/2016/7295390
[24]	Deretic V, Delgado M, Vergne I, et al. Autophagy in immunity against Mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr Top Microbiol Immunol, 2009, 335:169-188. doi: 10.1007/978-3-642-00302-8_8. doi: 10.1007/978-3-642-00302-8_8 pmid: 19802565
[25]	吴雪琼, 吴长有. 结核病免疫学. 北京: 人民卫生出版社, 2016.
[26]	刘晓, 吴雪琼. 中药治疗耐多药肺结核的研究进展. 中国防痨杂志, 2016, 38(1): 53-56. doi: 10.3969/j.issn.1000-6621.2016.01.012. doi: 10.3969/j.issn.1000-6621.2016.01.012
[27]	Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med, 2007, 7(4):373-386. doi: 10.2174/156652407780831557. doi: 10.2174/156652407780831557 pmid: 17584077
[28]	Joshi L, Chelluri LK, Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: A concise review. Arch Immunol Ther Exp(Warsz), 2015, 63(6): 427-433. doi: 10.1007/s00005-015-0347-9. doi: 10.1007/s00005-015-0347-9
[29]	付亮, 梁娟, 张国良, 等. γδT细胞在结核病免疫治疗的研究及其应用前景. 中国防痨杂志, 2019, 41(6):695-699. doi: 10.3969/j.issn.1000-6621.2019.06.019. doi: 10.3969/j.issn.1000-6621.2019.06.019
[30]	Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med, 2020, 9(7):2352-2362. doi: 10.1002/cam4.2868. doi: 10.1002/cam4.2868 URL

结核病免疫辅助治疗现状与挑战

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	中国防痨协会结核病控制专业分会, 中国防痨协会青年分会, 《中国防痨杂志》编辑委员会. 中国结核病数字服药依从性技术应用指南[J]. 中国防痨杂志, 2025, 47(4): 385-397.
[2]	李锦浩, 胡冬梅, 徐彩红. 结核病防治医务工作者开展预防性抗结核治疗工作意愿调查及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 398-407.
[3]	李玉红, 梅金周, 苏伟, 阮云洲, 刘玉舒, 赵雁林, 刘小秋. 2015—2021年全国65岁及以上老年利福平耐药肺结核患者治疗转归及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 408-415.
[4]	姜雪, 白云龙, 马建军, 安源, 杨帆, 赵庆龙. 2020—2023年吉林省利福平耐药肺结核患者诊治延迟现状及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 416-424.
[5]	吴璇, 张艳秋, 徐吉英, 孟丹, 孙定勇. 2019—2023年河南省肺结核合并糖尿病患者治疗转归影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 425-431.
[6]	安源, 白云龙, 赵庆龙, 马建军, 姜雪, 潘艳, 高迎, 高智慧. 2018—2022年吉林省肺结核合并糖尿病患者治疗转归情况及影响因素分析[J]. 中国防痨杂志, 2025, 47(4): 432-438.
[7]	冯畏, 郑海伦, 孟炜丽, 罗萍. 2018—2023年北京市西城区结核病防治机构登记管理肺结核患者到位前漏报情况分析[J]. 中国防痨杂志, 2025, 47(4): 439-443.
[8]	胡一凡, 杜博平, 吴亚东, 朱传智, 张蓝月, 贾红彦, 孙琦, 潘丽萍, 张宗德, 李自慧. Mce4C蛋白参与结核分枝杆菌摄取利用胆固醇的实验研究[J]. 中国防痨杂志, 2025, 47(4): 444-453.
[9]	盛杰, 洪凯峰, 米尔扎提·艾沙, 唐伟, 地里下提·阿不力孜. 白细胞介素22和p38 MAPK信号通路抑制骨关节结核骨质破坏的作用机制研究[J]. 中国防痨杂志, 2025, 47(4): 454-459.
[10]	王颖超, 刘唯夷, 姬秀秀, 尚雪恬, 贾红彦, 张蓝月, 孙琦, 杜博平, 朱传智, 潘丽萍, 张宗德. 结核病患者外周血单个核细胞内环状RNA表达谱分析及诊断标识的鉴定[J]. 中国防痨杂志, 2025, 47(4): 460-470.
[11]	朱明智, 邵燕琴, 范大鹏, 刘立宾, 梅宾, 戴玲珊, 蔡龙. 尿液脂阿拉伯甘露聚糖抗原检测对肺外结核的诊断价值[J]. 中国防痨杂志, 2025, 47(4): 471-476.
[12]	郝明晓, 米洁, 许宗仪. 延续性护理路径在结核性脑膜炎患者中的应用效果分析[J]. 中国防痨杂志, 2025, 47(4): 477-481.
[13]	尚希钰, 张慧芳, 曹玉清, 熊一白, 纪鑫毓, 田雅欣, 李佳佳, 王倪, 马艳. 基于文献计量学的结核病中医药基础研究全球研究现状及热点分析[J]. 中国防痨杂志, 2025, 47(4): 482-497.
[14]	秦丽莉, 杨澄清, 麦洪珍, 徐齐峰, 薛新颖, 路希维. 结核后肺曲霉病的临床诊疗研究进展[J]. 中国防痨杂志, 2025, 47(4): 498-504.
[15]	罗莉, 罗林紫, 尹曲华, 周磊, 卢志斌, 丁衍, 肖阳宝. 淋巴结瘘型气管支气管结核的支气管镜下诊疗进展[J]. 中国防痨杂志, 2025, 47(4): 505-512.